Höchsmann, Britta http://orcid.org/0000-0003-2257-6601
Peffault de Latour, Regis http://orcid.org/0000-0001-6222-4753
Hill, Anita http://orcid.org/0000-0001-9131-0896
Röth, Alexander http://orcid.org/0000-0003-4414-7699
Devos, Timothy http://orcid.org/0000-0002-6881-417X
Patriquin, Christopher J. http://orcid.org/0000-0002-2089-8650
Chou, Wen-Chien http://orcid.org/0000-0003-2967-698X
Jain, Deepak
Zu, Ke http://orcid.org/0000-0002-8399-7779
Wu, Chuntao http://orcid.org/0000-0002-8860-8402
Lee, Jong Wook http://orcid.org/0000-0003-2949-4166
Funding for this research was provided by:
Alexion, AstraZeneca Rare Disease
Universität Ulm
Article History
Received: 27 October 2022
Accepted: 4 August 2023
First Online: 5 September 2023
Declaration
:
: The institutional review boards (or equivalent) of participating centers approved the Registry.
: Written informed consent was obtained from all individual participants who were included in the International PNH Registry.
: <b>B Höchsmann</b> has received honoraria, consulting fees, and research support (to University of Ulm) from Alexion, AstraZeneca Rare Disease; Novartis; Ra Pharma; Roche; Sobi; and Apellis. <b>R Peffault de Latour</b> has received honoraria, consulting fees, and research support from Alexion, AstraZeneca Rare Disease; Pfizer; and Novartis; and has received research support from Amgen. <b>A Hill</b> has received honoraria and/or consulting fees from Akari Therapeutics; Alexion, AstraZeneca Rare Disease; Apellis; Bioverativ; Novartis; Ra Pharma; Regeneron; and Roche; and is currently employed by Alexion, AstraZeneca Rare Disease. <b>A Röth</b> has received honoraria from Alexion, AstraZeneca Rare Disease; Roche Pharma; Novartis; Sanofi; Bioverativ; BioCryst; Sobi; Apellis; and Kira. <b>T Devos</b> has received consultancy fees from Alexion, AstraZeneca Rare Disease; Gilead; Novartis; and Janssen; and has participated in advisory boards for Novartis, Gilead, and Janssen. <b>CJ Patriquin</b> has received an unrestricted educational grant from Alexion, AstraZeneca Rare Disease. He has participated in advisory boards with Alexion, AstraZeneca Rare Disease; Apellis; Sanofi; and Biocryst. He is/has been site investigator for trials with Alexion, AstraZeneca Rare Disease; Apellis; Ra Pharma; and Sanofi. <b>W–C Chou</b> has nothing to declare. <b>D Jain</b> is employed by Alexion, AstraZeneca Rare Disease. <b>K Zu</b> and <b>C Wu</b> were employed by Alexion, AstraZeneca Rare Disease, at the time of study. <b>JW Lee</b> has received honoraria, consulting fees, and research support from Alexion, AstraZeneca Rare Disease.